CSPC PHARMA (01093) announced that its self-developed chemical Class 1 new drug, SYH2061 injection (a dual-chain small interfering RNA (siRNA) drug), has received approval from the National Medical Products Administration of the People's Republic of China to initiate clinical trials in the country. This product is an siRNA drug that achieves liver-targeted delivery via conjugation with N-acetylgalactosamine (GalNAc) and targets complement protein C5 (C5) through subcutaneous administration, effectively reducing C5 levels. By optimizing sequences and employing chemical modifications, this product offers a more enduring gene silencing effect. It stands as the first domestically developed ultra-long-acting siRNA drug for lowering C5 levels to enter the clinical trial phase, intended for treating IgA nephropathy and other complement-mediated diseases. Preclinical studies indicate that this product outperforms similar siRNA products in terms of drug activity and duration of efficacy, demonstrating prolonged effects, good safety profiles, and high patient adherence, making it a valuable candidate for clinical development.